Favourable effect of statin therapy on early survival benefit at the time of percutaneous coronary intervention for ST-elevation myocardial infarction and shock

EuroIntervention

Volumn 6, Issue 3, 2010, Pages 350-355

  Garot, Philippe ^a   Bendaoud, Nabil ^a   Lefèvre, Thierry ^a   Morice, Marie Claude ^a  

^a INSTITUT CARDIOVASCULAIRE PARIS SUD   (France)

Author keywords

Angioplasty; Mortality; Myocardial infarction; Shock; Statins; Stents

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TICLOPIDINE;

ADULT; AGED; ARTICLE; CARDIOGENIC SHOCK; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; POPULATION RESEARCH; PROPENSITY SCORE; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL TIME; CAUSE OF DEATH; COMPARATIVE STUDY; ELECTROCARDIOGRAPHY; FRANCE; HEART INFARCTION; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CAUSE OF DEATH; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; FRANCE; HOSPITAL MORTALITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; RETROSPECTIVE STUDIES; SHOCK, CARDIOGENIC; SURVIVAL RATE;

EID: 79952782396     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV6I3A58     Document Type: Article

References (24)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009. (Pubitemid 26338729)
3. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. A randomized controlled trial. JAMA. 2001;285:1711-1718.
4. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001;285:430-436. (Pubitemid 32097261)
5. Merten M, Dong JF, Lopez JA, Thiagarajan P. Cholesterol sulfate: a new adhesive molecule for platelets. Circulation. 2001;103:2032-2034. (Pubitemid 32373002)
6. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 1995;92:3172-3177.
7. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation. 1999;99:3227-3233. (Pubitemid 29293431)
8. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on Creactive protein in patients with coronary artery disease. Lancet. 1999;353:118-119. (Pubitemid 29088085)
9. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103:1933-1935. (Pubitemid 32322218)
10. Vyas AK, Guo H, Moss AJ, Olshansky B, McNitt SA, Hall WJ, Zareba W, Steinberg JS, Fischer A, Ruskin J, Andrews ML. MADIT-II Research Group. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006;47:769-73. (Pubitemid 43243099)
11. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281.
12. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, Harrington RA, Califf RM, Ohman EM, Kleiman NS, Keltai M, Wilcox RG, Vahanian A, Armstrong PW, Lauer MS. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001;357:1063-1068. (Pubitemid 32322536)
13. Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, French WJ; National Registry of Myocardial Infarction 4 Investigators. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol. 20051;96:611-6.
14. Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD; Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105:1446-52.
15. Hoffmann R, Haager P, Suliman H, Christott P, Radke P, Blindt R, Kelm M. Effect of statin therapy before Q-wave myocardial infarction on myocardial perfusion. Am J Cardiol. 2008;101:139-43.
16. Bunch TJ, Kottke TE, Lopez-Jimenez F, Mahapatra S, Elesber AA, White RD. A comparative analysis of short- and long-term outcomes after ventricular fibrillation out-of-hospital cardiac arrest in patients with ischemic and nonischemic heart disease. Am J Cardiol. 2006;98:857-60. (Pubitemid 44402251)
17. Klein LW, Shaw RE, Krone RJ, Brindis RG, Anderson HV, Block PC, McKay CR, Hewitt K, Weintraub WS; American College of Cardiology National Cardiovascular Data Registry. Mortality after emergent percutaneous coronary intervention in cardiogenic shock secondary to acute myocardial infarction and usefulness of a mortality prediction model. Am J Cardiol. 2005;96:35-41. (Pubitemid 40853936)
18. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, Buller CE, Jacobs AK, Slater JN, Col J, McKinlay SM, LeJemtel TH. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med. 1999;341:625-34.
19. Briel M, Schwartz GG, Thompson PL, Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es GA, Kayikçioglu M, Arntz HR, den Hartog FR, Veeger NJ, Colivicchi F, Dupuis J, Okazaki S, Wright RS, Bucher HC, Nordmann AJ. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA. 2006;295:2046-56. (Pubitemid 44794006)
20. Aikawa M, Rabkin E, Okada Y, Voglic SJ, Clinton SK, Brinckerhoff CE, Sukhova GK, Libby P. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation. 1998;97:2433-2444. (Pubitemid 28278188)
21. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129-1135. (Pubitemid 28152885)
22. Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/ CRP evaluation (PRINCE). A randomized trial and cohort study. JAMA. 2001;286:64-70. (Pubitemid 32606333)
23. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shefferd J, Willerson JT, Glynn RJ; JUPITER Study group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
24. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM Jr., Shepherd J, Westendorp RG, De Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW. The benefit of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials. BMJ. 2009;338:b2376.